Trial reportEuropean journal of endocrinology2021
Metabolic health during a randomized controlled lifestyle intervention in women with PCOS.
Trial report in European journal of endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 6 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- The effect of lifestyle interventions in women with polyendocrine metabolic ovarian syndrome: A systematic review and meta-analysis.PLoS medicine · 2026Pooled it
- Pre-conception weight loss interventions in women with polycystic ovary syndrome and the effect on perinatal outcomes: A quantitative synthesis of surrogate outcomes.Diabetes, obesity & metabolism · 2025Pooled it
- The clinical efficacy of digital health interventions in patients with polycystic ovary syndrome: a systematic review and meta-analysis.Journal of health, population, and nutrition · 2025Pooled it
- Pooled it
- Pooled it
- The effects of behavioral intervention on anthropometric, clinical, and biochemical parameters in patients with polycystic ovary syndrome: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- A randomised controlled trial on the effects of a structural education module among women with polycystic ovarian syndrome on nutrition and physical activity changes.BMC women's health · 2022Trial
- Algae-Derived Bioactives Reprogram the Gut-SIRT1-Kisspeptin Axis in Polycystic Ovary Syndrome.Marine drugs · 2026Review
- Article
- Associations of nutrition knowledge with dietary preferences, symptom burden, and quality of life in women with polycystic ovary syndrome.Frontiers in nutrition · 2026Article
- Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome.Current obesity reports · 2025Review
- Triglyceride glucose index - body mass index predicts insulin resistance, metabolic syndrome and associates with impaired ovulation in Chinese women with polycystic ovary syndrome.Frontiers in endocrinology · 2025Article
- Article
- Polycystic Ovary Syndrome and the Internet of Things: A Scoping Review.Healthcare (Basel, Switzerland) · 2024Article
- Effects of Regular Exercise on the Biochemical, Oxidative, and Inflammatory Profiles and Quality of Life in Older Spaniards with Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2024Article
- The Impact of Polycystic Ovary Syndrome (PCOS) on the Risk of Developing Ovarian Cancer and Thyroid Disorders: A Comprehensive Review.Endocrine, metabolic & immune disorders drug targets · 2024Review
- Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics.Frontiers in microbiology · 2024Article
- The dynamic nexus: exploring the interplay of BMI before, during, and after pregnancy with Metabolic Syndrome (MetS) risk in Chinese lactating women.BMC public health · 2023Article
- Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies.Journal of clinical medicine · 2023 · on this mapReview
- Heterogeneity and associated factors of patients with polycystic ovary syndrome health behaviors: a latent class analysis.BMC endocrine disorders · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextWomen with polycystic ovary syndrome (PCOS) have an increased risk of metabolic syndrome (MetS). Both PCOS and MetS are associated with excess weight.
objectiveTo examine the effect of a three-component lifestyle intervention (LSI) with or without short message service (SMS+ or SMS-, respectively) on the prevalence and severity of MetS and metabolic parameters, compared to care as usual (CAU).
designRandomized controlled trial.
methodsWomen diagnosed with PCOS and a BMI >25 kg/m2 (n = 183) were either assigned to a 1-year three-component (cognitive behavioural therapy, diet, and exercise) LSI, with or without SMS support, or to CAU which provided weight-loss advice only. Main outcome measures included changes in the prevalence of MetS, the continuous MetS severity z-score (cMetS z-score), metabolic parameters, and the impact of weight loss.
resultsAfter 1 year, the decrease in the cMetS z-score was greater in the SMS+ group than the CAU group (-0.39, P = 0.015). The prevalence of MetS changed with -21.6% (P = 0.037), -16.5% (P = 0.190), and +7.0% (P = 0.509) in both LSI groups and CAU group, respectively. A post hoc analysis for both LSI groups combined vs CAU resulted in a MetS difference of -25.9% (P = 0.046). Moreover, weight loss per se resulted in significantly favourable effects on all metabolic parameters.
conclusionsThis three-component LSI was more successful in improving metabolic health compared to CAU. Therefore, we recommend this intervention to women with PCOS and excess weight, provided that a clinically relevant weight loss is being pursued.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.